EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Young Eun Chon, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Hong Jae Chon iD, Beom Kyung Kim iD

Cancer Medicine · 2023-02 · 12 (3) · 2731-2738

DOI: 10.1002/cam4.5161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.08.2022. Verfasst von Young Eun Chon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since atezolizumab plus bevacizumab (ATE+BEV) regimen for patients with unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data are lacking. We evaluated efficacy, safety, and predictive biomarkers for survival in patients receiving ATE+BEV.

Methods

Between 2020 and 2021, HCC patients receiving ATE+BEV at academic teaching hospitals were recruited. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.).

Results

Among 121 patients enrolled, the median age was 63 years, with male predominance (82.6%). Complete response, partial response, stable disease, and progressive disease were identified in 2.5%, 26.4%, 54.5%, and 16.6%, respectively. Patients with alpha‐fetoprotein and des‐gamma‐carboxy prothrombin (DCP) response, defined as ≥30% and ≥50% decreases, respectively, at the first response evaluation relative to baseline, and those with neutrophil‐to‐lymphocyte ratio (NLR)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMaleMiddle AgedFemaleBevacizumabBiomarkersAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

atezolizumabbevacizumabdes-gamma-carboxy prothrombinhepatocellular carcinomaneutrophil to lymphocyte ratio

Substanzen

BevacizumabBiomarkersatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Medical oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Hong Jae Chon, Beom Kyung Kim

Zitieren

APA

Chon, Y. E., Cheon, J., Kim, H., Kang, B., Ha, Y., Kim, D. Y., Hwang, S. G., Chon, H. J., & Kim, B. K. (2023). Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Medicine, 12(3), 2731-2738. https://doi.org/10.1002/cam4.5161

Vancouver

Chon YE, Cheon J, Kim H, Kang B, Ha Y, Kim DY, et al. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Medicine. 2023;12(3):2731-2738. doi:10.1002/cam4.5161

BibTeX
@article{Chon2023,
  author = {Chon, Young Eun and Cheon, Jaekyung and Kim, Hyeyeong and Kang, Beodeul and Ha, Yeonjung and Kim, Do Young and Hwang, Seong Gyu and Chon, Hong Jae and Kim, Beom Kyung},
  title = {Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {2731--2738},
  doi = {10.1002/cam4.5161}
}
Kostenlos starten →